Targeting cancer-associated fibroblasts: Challenges, opportunities and future directions.

Cancer-associated fibroblasts (CAFs) are a common cell in the tumour microenvironment with diverse tumour-promoting functions. Their presence in tumours is commonly associated with poor prognosis making them attractive therapeutic targets, particularly in the context of immunotherapy where CAFs have been shown to promote resistance to checkpoint blockade. Previous attempts to inhibit CAFs clinically have not been successful, however, in part due to a lack of understanding of CAF heterogeneity and function, with some fibroblast populations potentially being tumour suppressive. Recent single-cell transcriptomic studies have advanced our understanding of fibroblast phenotypes in normal tissues and cancers, allowing for a more precise characterisation of CAF subsets and providing opportunities to develop new therapies. Here we review recent advances in the field, focusing on the evolving area of therapeutic CAF targeting.
Competing Interests: Declaration of Competing Interest C.J. Hanley and G.J. Thomas are co-inventors on patent WO2019086579 for the use of NOX inhibitors in cancer. B.H. Jenkins and J.F. Buckingham have no conflicts of interest to declare.
(Copyright © 2022 Elsevier Inc. All rights reserved.)